CSIMarket
 
Exscientia Plc  (NASDAQ: EXAI)
Other Ticker:  
 
 
Price: $4.8400 $0.15 3.198%
Day's High: $4.85 Week Perf: -13.73 %
Day's Low: $ 4.49 30 Day Perf: -4.91 %
Volume (M): 1,510 52 Wk High: $ 7.20
Volume (M$): $ 7,308 52 Wk Avg: $5.26
Open: $4.63 52 Wk Low: $3.80



 Market Capitalization (Millions $) 241
 Shares Outstanding (Millions) 50
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 0
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 6

Exscientia Plc
Exscientia Plc is a leading artificial intelligence (AI)-driven drug discovery company. The company utilizes machine learning algorithms and AI approaches to design and develop new drugs, with the aim of accelerating the drug discovery process. Exscientia combines computational technologies with human expertise to discover and optimize potential drug candidates, enabling the development of new therapies for various diseases. The company partners with pharmaceutical companies and uses its advanced technology platform to help identify and prioritize drug targets, design molecules, and optimize lead compounds. Through its innovative approach, Exscientia aims to revolutionize the pharmaceutical industry by delivering safer and more effective drugs in a faster and more cost-efficient manner.


   Company Address: The Schr??dinger Building Oxford 0
   Company Phone Number: 1865 818941   Stock Exchange / Ticker: NASDAQ EXAI


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABSI        5.72% 
SDGR   -7.84%    
• View Complete Report
   



Business Update

Milestones Achieved Exscientia and Sanofi Advance in Collaborative Drug Development

Published Thu, Oct 17 2024 4:19 AM UTC

In a significant stride for collaborative drug development, Exscientia plc headquartered in , England and publicly traded on Nasdaq as EXAI has announced the progression of two drug development programs in partnership with Sanofi. These advancements mark crucial milestones in the ongoing collaboration between the two companies, underscoring the potential of AI-driven drug di...

Business Update

Exscientias Strategic Breakthrough Milestone Achievements Propel Collaboration with Sanofi into Lead Optimization ...

Published Wed, Oct 16 2024 12:47 PM UTC

In a significant stride for drug discovery innovation, Exscientia plc (Nasdaq: EXAI) has successfully advanced two discovery programmes in its collaboration with global biopharmaceutical giant Sanofi. The announcement comes with the achievement of critical milestones that have resulted in Exscientia being awarded an impressive $15 million in milestone payments. This success ...

Business Update

Exscientias Innovative Leap New Preclinical Data and Strategic Advancements in AI-Driven Drug Development Set to Tra...

Published Thu, Oct 10 2024 12:47 AM UTC

In a groundbreaking announcement today, Exscientia plc (Nasdaq: EXAI) underscored its commitment to revolutionizing cancer treatment by unveiling new preclinical data concerning its precision-engineered LSD1 (lysine-specific demethylase 1) and MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1) inhibitors at the 36th EORTC-NCI-AACR Symposium 2024, held...

Business Update

Advancements in AI-Designed Precision Inhibitors Exscientia Unveils New Preclinical Data for LSD1 and MALT1 Inhibitor...

Published Wed, Oct 9 2024 12:47 PM UTC

Summary Exscientia plc, a leader in artificial intelligence-driven drug discovery, is poised to present significant new preclinical findings concerning its LSD1 and MALT1 inhibitors at the upcoming 36th EORTC-NCI-AACR (ENA) Symposium 2024, scheduled for October 23-25 in Barcelona, Spain. These developments mark a significant step forward in Exscientia s commitment to advanci...

Business Update

Accelerating Breakthroughs Exscientia Acquires Potential Best-in-Class CDK7 Inhibitor, Paving the Way for Transformat...

Published Thu, Jul 18 2024 11:56 AM UTC

Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data ReadoutOXFORD, England - Exscientia, a leading artificial intelligence (AI) driven biopharmaceutical company, has recently announced its acquisition of GT Apeiron s share of the oral CDK7 inhibitor programme. This strategic move grants Exscientia complete control o...










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com